Country for PR: United States
Contributor: PR Newswire New York
Monday, June 19 2017 - 11:04
AsiaNet
4C Medical's Novel Mitral Regurgitation Therapy Highlighted at TVT Innovation Forum
BROOKLYN PARK, Minnesota, June 19, 2017 /PRNewswire-AsiaNet/ --

-- Presentation Featured the Company's Supra-Annular Implant, the First 
Transcatheter Mitral Regurgitation Therapy with Atrial-Only Fixation

4C Medical Technologies, Inc., a developer of minimally invasive therapies for 
structural heart disease, today announced that its medical device therapy for 
mitral regurgitation (MR) was featured in the Transcatheter Valve Therapies 
(TVT) Innovation Forum which took place June 14, 2017 in Chicago, IL. The 
company is developing the first MR therapy that preserves the native mitral 
valve and left ventricle using a supra-annular, atrial-only fixation 
technology. The novel design eliminates known issues of current transcatheter 
mitral valve replacement (TMVR) technologies which rely on placement and 
fixation in the native mitral annulus and left ventricle. 

Logo - 
http://mma.prnewswire.com/media/521129/4C_Medical_Technologies_Inc___Logo.jpg

"4C Medical's mitral valve is an innovative and simple solution for a very 
common problem, and its unique mechanism will allow treatment of many patients 
not suitable for current TMVR devices," said Philippe Genereux, MD. "30-day 
pre-clinical results are promising and demonstrate concept feasibility and 
safety, with no hemodynamic compromise, no thrombus, and mild-to-no MR as 
confirmed by echocardiography."

Dr. Genereux presented "4C Medical Valve: A Novel Transcatheter MR Treatment 
Technology" and facilitated subsequent roundtable discussions with audience 
Q&A. He is Co-Director of the Structural Heart Program at the Gagnon 
Cardiovascular Institute of Morristown Medical Center (Morristown, NJ) and a 
practicing Interventional Cardiologist at Hopital du Sacre-Coeur de Montreal 
(Montreal, Canada).

"The main challenges encountered by current TMVR devices are related to the 
complexity of the mitral valve anatomy and the multitude of MR mechanisms," 
said Dr. Genereux. "With its supra-annular position in the left atrium, the 4C 
Medical device preserves the native valve apparatus and avoids all issues 
related to the complexity and dynamism of the mitral annulus, making the device 
suitable for patients independent of their MR mechanism. This unique approach 
promotes healthy left ventricular remodeling and healing, and eliminates the 
complications that are associated with current TMVR devices, such as left 
ventricular outflow tract obstruction, device embolization and early device 
fatigue failure."

"We are dedicated to innovating therapies for structural heart disease through 
clinical research in partnership with Key Opinion Leaders," said Robert 
Thatcher, CEO of 4C Medical Technologies, Inc. "More than half of symptomatic 
MR patients are not candidates for surgery, and we are driven to develop new 
solutions that clinicians can use to improve the quality of life for these 
patients."

About Mitral Regurgitation 
Mitral regurgitation (MR) is a common heart valve disease affecting nearly 10 
percent of Americans aged > or = 75 years.(1) MR occurs when the mitral valve 
leaflets do not close properly and allow blood in the left ventricle to leak 
back into the left atrium. It is a progressive disease and if left untreated, 
MR can lead to atrial fibrillation, pulmonary hypertension, heart failure and 
death.

About 4C Medical Technologies, Inc.
4C Medical Technologies, Inc. is a medical device company developing minimally 
invasive therapies for structural heart disease, focusing initially on mitral 
regurgitation (MR) therapy and subsequently on tricuspid regurgitation therapy. 
The company's unique supra-annular implant is the first MR therapy with 
atrial-only fixation, thereby eliminating known issues associated with 
transcatheter MR replacement technologies which rely on placement and fixation 
in the native mitral annulus and left ventricle. 

    1.  Nkomo VT, et al. Burden of valvular heart diseases: a population-
        based study. Lancet. 2006;368:1005-11. doi: 10.1016/S0140-
        6736(06)69208-8.

Media Contacts
Robert Thatcher
Chief Executive Officer
+1 (612) 600-8951
rthatcher@4CMed.com

Jim Flaherty
Chief Financial Officer
+1 (612) 599-0650
jflaherty@4CMed.com 

SOURCE: 4C Medical Technologies, Inc.
Translations

Japanese